In regards to the CLBP trial I was hoping someone in the medical field would be able to enlighten me, looking through the endpoints on the clinical gov website it seems there are subjective scores (VAS and ODI).
Would it not have made sense to have an objective end point such as MRI representing disc reg. eneration between the groups in the study? My understanding of pain is that pain does not equal tissue damage and is our own experiences and personal input which determines our pain. So even if the stem cells work and regenerate the disc, the individuals still may experience pain which would not show improvement in the treatment group (due to subjective measures).
Lets hear your thoughts
MSB Trading 2020 - a new dawn, page-12685
-
- There are more pages in this discussion • 386 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.51 |
Change
0.020(1.34%) |
Mkt cap ! $1.724B | |||
| Open | High | Low | Value | Volume |
| $1.57 | $1.58 | $1.41 | $18.15M | 12.09M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3418 | $1.50 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.51 | 24361 | 5 |
View Market Depth
| Last trade - 16.10pm 07/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |